{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:19:39Z","timestamp":1790741979534,"version":"4.1.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T00:00:00Z","timestamp":1735516800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T00:00:00Z","timestamp":1735516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"DOI":"10.1007\/s12020-024-04150-2","type":"journal-article","created":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T12:23:50Z","timestamp":1735561430000},"page":"1314-1322","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Increased ferritin with contraceptives containing ethinyl estradiol drospirenone in polycystic ovary syndrome: a paradox of iron storage and iron deficiency"],"prefix":"10.1007","volume":"87","author":[{"given":"Naile","family":"Gokkaya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gizem","family":"Gecmez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serhat","family":"Ozcelik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mithat","family":"Biyikli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kadriye","family":"Aydin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,30]]},"reference":[{"issue":"2","key":"4150_CR1","doi-asserted-by":"publisher","first-page":"G43","DOI":"10.1093\/ejendo\/lvad096","volume":"189","author":"HJ Teede","year":"2023","unstructured":"H.J. Teede, C.T. Tay, J.J.E. Laven et al., Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Eur. J. Endocrinol. 189(2), G43\u2013G64 (2023). https:\/\/doi.org\/10.1093\/ejendo\/lvad096","journal-title":"Eur. J. Endocrinol."},{"issue":"12","key":"4150_CR2","doi-asserted-by":"publisher","first-page":"2841","DOI":"10.1093\/humrep\/dew218","volume":"31","author":"G Bozdag","year":"2016","unstructured":"G. Bozdag, S. Mumusoglu, D. Zengin, E. Karabulut, B.O. Yildiz, The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis. Hum. Reprod. 31(12), 2841\u20132855 (2016). https:\/\/doi.org\/10.1093\/humrep\/dew218","journal-title":"Hum. Reprod."},{"issue":"1","key":"4150_CR3","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.fertnstert.2003.10.004","volume":"81","author":"Rotterdam ESHRE\/ASRM-Sponsored PCOS Consensus Workshop Group","year":"2004","unstructured":"Rotterdam ESHRE\/ASRM-Sponsored PCOS Consensus Workshop Group, Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil. Steril. 81(1), 19\u201325 (2004). https:\/\/doi.org\/10.1016\/j.fertnstert.2003.10.004","journal-title":"Fertil. Steril."},{"issue":"12","key":"4150_CR4","doi-asserted-by":"publisher","first-page":"4565","DOI":"10.1210\/jc.2013-2350","volume":"98","author":"RS Legro","year":"2013","unstructured":"R.S. Legro, S.A. Arslanian, D.A. Ehrmann et al., Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 98(12), 4565\u20134592 (2013). https:\/\/doi.org\/10.1210\/jc.2013-2350.","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"4150_CR5","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.ecl.2020.11.001","volume":"50","author":"LG Cooney","year":"2021","unstructured":"L.G. Cooney, A. Dokras, Cardiometabolic risk in polycystic ovary syndrome: current guidelines. Endocrinol. Metab. Clin. North Am. 50(1), 83\u201395 (2021). https:\/\/doi.org\/10.1016\/j.ecl.2020.11.001","journal-title":"Endocrinol. Metab. Clin. North Am."},{"key":"4150_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2023.1186990","volume":"10","author":"C Zhuang","year":"2023","unstructured":"C. Zhuang, X. Luo, W. Wang, R. Sun, M. Qi, J. Yu, Corrigendum: cardiovascular risk according to body mass index in reproductive-aged women with polycystic ovary syndrome: a systematic review and meta-analysis. Front. Cardiovasc. Med. 10, 1186990 (2023). https:\/\/doi.org\/10.3389\/fcvm.2023.1186990.","journal-title":"Front. Cardiovasc. Med."},{"issue":"1","key":"4150_CR7","doi-asserted-by":"publisher","first-page":"R4","DOI":"10.1093\/ejendo\/lvad083","volume":"189","author":"MM Ollila","year":"2023","unstructured":"M.M. Ollila, A. Hoek, T.T. Piltonen, The association between polycystic ovary syndrome and early cardiovascular disease morbidity strengthens. Eur. J. Endocrinol. 189(1), R4\u2013R5 (2023). https:\/\/doi.org\/10.1093\/ejendo\/lvad083","journal-title":"Eur. J. Endocrinol."},{"issue":"1","key":"4150_CR8","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1093\/ejendo\/lvad082","volume":"189","author":"M Forslund","year":"2023","unstructured":"M. Forslund, J. Melin, S. Alesi et al., Different kinds of oral contraceptive pills in polycystic ovary syndrome: a systematic review and meta-analysis. Eur. J. Endocrinol. 189(1), S1\u2013S16 (2023). https:\/\/doi.org\/10.1093\/ejendo\/lvad082","journal-title":"Eur. J. Endocrinol."},{"issue":"3","key":"4150_CR9","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1111\/cen.13795","volume":"89","author":"HJ Teede","year":"2018","unstructured":"H.J. Teede, M.L. Misso, M.F. Costello et al., Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Clin. Endocrinol. 89(3), 251\u2013268 (2018). https:\/\/doi.org\/10.1111\/cen.13795","journal-title":"Clin. Endocrinol."},{"key":"4150_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1390013","volume":"15","author":"M Wang","year":"2024","unstructured":"M. Wang, B.Q. Zhang, S. Ma, Y. Xu, D.H. Zhao, J.S. Zhang, C.J. Li, X. Zhou, L.W. Zheng, Broadening horizons: the role of ferroptosis in polycystic ovary syndrome. Front. Endocrinol. 15, 1390013 (2024). https:\/\/doi.org\/10.3389\/fendo.2024.1390013. Aug 2PMID: 39157678; PMCID: PMC11327064","journal-title":"Front. Endocrinol."},{"issue":"1","key":"4150_CR11","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20212234","volume":"43","author":"M Mathew","year":"2023","unstructured":"M. Mathew, S. Sivaprakasam, J.L. Phy, Y.D. Bhutia, V. Ganapathy, Polycystic ovary syndrome and iron overload: biochemical link and underlying mechanisms with potential novel therapeutic avenues. Biosci. Rep. 43(1), BSR20212234 (2023). https:\/\/doi.org\/10.1042\/BSR20212234.","journal-title":"Biosci. Rep."},{"issue":"8","key":"4150_CR12","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/j.tips.2021.05.001","volume":"42","author":"K Roemhild","year":"2021","unstructured":"K. Roemhild, F. von Maltzahn, R. Weiskirchen, R. Kn\u00fcchel, S. von Stillfried, T. Lammers, Iron metabolism: pathophysiology and pharmacology. Trends Pharmacol. Sci. 42(8), 640\u2013656 (2021). https:\/\/doi.org\/10.1016\/j.tips.2021.05.001.","journal-title":"Trends Pharmacol. Sci."},{"issue":"10","key":"4150_CR13","doi-asserted-by":"publisher","first-page":"2613","DOI":"10.1007\/s00125-012-2633-y","volume":"55","author":"J Montonen","year":"2012","unstructured":"J. Montonen, H. Boeing, A. Steffen et al., Body iron stores and risk of type 2 diabetes: results from the European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam study. Diabetologia 55(10), 2613\u20132621 (2012). https:\/\/doi.org\/10.1007\/s00125-012-2633-y.","journal-title":"Diabetologia"},{"issue":"9","key":"4150_CR14","doi-asserted-by":"publisher","first-page":"3359","DOI":"10.1182\/blood-2002-10-3071","volume":"101","author":"JD Cook","year":"2003","unstructured":"J.D. Cook, C.H. Flowers, B.S. Skikne, The quantitative assessment of body iron. Blood 101(9), 3359\u20133364 (2003). https:\/\/doi.org\/10.1182\/blood-2002-10-3071","journal-title":"Blood"},{"issue":"2","key":"4150_CR15","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.fertnstert.2014.04.031","volume":"102","author":"JW Kim","year":"2014","unstructured":"J.W. Kim, K.M. Kang, T.K. Yoon, S.H. Shim, W.S. Lee, Study of circulating hepcidin in association with iron excess, metabolic syndrome, and BMP-6 expression in granulosa cells in women with polycystic ovary syndrome. Fertil. Steril. 102(2), 548\u2013554.e2 (2014). https:\/\/doi.org\/10.1016\/j.fertnstert.2014.04.031","journal-title":"Fertil. Steril."},{"issue":"8","key":"4150_CR16","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.2337\/diacare.28.8.2042","volume":"28","author":"HF Escobar-Morreale","year":"2005","unstructured":"H.F. Escobar-Morreale, M. Luque-Ram\u00edrez, F. Alvarez-Blasco, J.I. Botella-Carretero, J. Sancho, J.L. San Mill\u00e1n, Body iron stores are increased in overweight and obese women with polycystic ovary syndrome. Diabetes Care 28(8), 2042\u20132044 (2005). https:\/\/doi.org\/10.2337\/diacare.28.8.2042","journal-title":"Diabetes Care"},{"issue":"9","key":"4150_CR17","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.2337\/dc07-0642","volume":"30","author":"M Luque-Ram\u00edrez","year":"2007","unstructured":"M. Luque-Ram\u00edrez, F. Alvarez-Blasco, J.I. Botella-Carretero, R. Sanch\u00f3n, J.L. San Mill\u00e1n, H.F. Escobar-Morreale, Increased body iron stores of obese women with polycystic ovary syndrome are a consequence of insulin resistance and hyperinsulinism and are not a result of reduced menstrual losses. Diabetes Care 30(9), 2309\u20132313 (2007). https:\/\/doi.org\/10.2337\/dc07-0642","journal-title":"Diabetes Care"},{"issue":"1","key":"4150_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s13048-019-0554-9","volume":"12","author":"S Behboudi-Gandevani","year":"2019","unstructured":"S. Behboudi-Gandevani, H. Abtahi, N. Saadat, M. Tohidi, F. Ramezani Tehrani, Effect of phlebotomy versus oral contraceptives containing cyproterone acetate on the clinical and biochemical parameters in women with polycystic ovary syndrome: a randomized controlled trial. J. Ovarian Res. 12(1), 78 (2019). https:\/\/doi.org\/10.1186\/s13048-019-0554-9. Published 2019 Aug 30","journal-title":"J. Ovarian Res."},{"issue":"13","key":"4150_CR19","doi-asserted-by":"publisher","first-page":"3864","DOI":"10.3390\/jcm11133864","volume":"11","author":"M Luque-Ram\u00edrez","year":"2022","unstructured":"M. Luque-Ram\u00edrez, A.E. Ortiz-Flores, M.\u00c1. Mart\u00ednez-Garc\u00eda et al., Effect of iron depletion by bloodletting vs. observation on oxidative stress biomarkers of women with functional hyperandrogenism taking a combined oral contraceptive: a randomized clinical trial. J. Clin. Med. 11(13), 3864 (2022). https:\/\/doi.org\/10.3390\/jcm11133864.","journal-title":"J. Clin. Med."},{"issue":"6","key":"4150_CR20","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/j.tjog.2014.11.025","volume":"54","author":"JH Yang","year":"2015","unstructured":"J.H. Yang, C.H. Chou, W.S. Yang, H.N. Ho, Y.S. Yang, M.J. Chen, Iron stores and obesity are negatively associated with ovarian volume and anti-M\u00fcllerian hormone levels in women with polycystic ovary syndrome. Taiwan J. Obstet. Gynecol. 54(6), 686\u2013692 (2015). https:\/\/doi.org\/10.1016\/j.tjog.2014.11.025","journal-title":"Taiwan J. Obstet. Gynecol."},{"issue":"3","key":"4150_CR21","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1053\/j.gastro.2006.07.007","volume":"131","author":"S Bekri","year":"2006","unstructured":"S. Bekri, P. Gual, R. Anty et al., Increased adipose tissue expression of hepcidin in severe obesity is independent from diabetes and NASH. Gastroenterology 131(3), 788\u2013796 (2006). https:\/\/doi.org\/10.1053\/j.gastro.2006.07.007","journal-title":"Gastroenterology"},{"issue":"9","key":"4150_CR22","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1172\/JCI20945","volume":"113","author":"E Nemeth","year":"2004","unstructured":"E. Nemeth, S. Rivera, V. Gabayan et al., IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J. Clin. Investig. 113(9), 1271\u20131276 (2004). https:\/\/doi.org\/10.1172\/JCI20945","journal-title":"J. Clin. Investig."},{"issue":"7","key":"4150_CR23","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1038\/oby.2009.319","volume":"18","author":"LM Tussing-Humphreys","year":"2010","unstructured":"L.M. Tussing-Humphreys, E. Nemeth, G. Fantuzzi et al., Elevated systemic hepcidin and iron depletion in obese premenopausal females. Obesity 18(7), 1449\u20131456 (2010). https:\/\/doi.org\/10.1038\/oby.2009.319","journal-title":"Obesity"},{"issue":"12","key":"4150_CR24","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1177\/1933719113488444","volume":"20","author":"F Moro","year":"2013","unstructured":"F. Moro, A. Morciano, A. Tropea et al., Effects of drospirenone-ethinylestradiol and\/or metformin on CD4(+)CD28(null) T lymphocytes frequency in women with hyperinsulinemia having polycystic ovary syndrome: a randomized clinical trial. Reprod. Sci. 20(12), 1508\u20131517 (2013). https:\/\/doi.org\/10.1177\/1933719113488444","journal-title":"Reprod. Sci."},{"issue":"3","key":"4150_CR25","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1111\/j.1365-2265.2012.04415","volume":"78","author":"N Cinar","year":"2013","unstructured":"N. Cinar, A. Harmanci, M. Bayraktar, B.O. Yildiz, Ethinyl estradiol-drospirenone vs ethinyl estradiol-drospirenone plus metformin in the treatment of lean women with polycystic ovary syndrome. Clin. Endocrinol. 78(3), 379\u2013384 (2013). https:\/\/doi.org\/10.1111\/j.1365-2265.2012.04415","journal-title":"Clin. Endocrinol."},{"issue":"1","key":"4150_CR26","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1111\/j.1365-2265.2012.04466.x","volume":"78","author":"A Harmanci","year":"2013","unstructured":"A. Harmanci, N. Cinar, M. Bayraktar, B.O. Yildiz, Oral contraceptive plus antiandrogen therapy and cardiometabolic risk in polycystic ovary syndrome. Clin. Endocrinol. 78(1), 120\u2013125 (2013). https:\/\/doi.org\/10.1111\/j.1365-2265.2012.04466.x","journal-title":"Clin. Endocrinol."},{"issue":"8","key":"4150_CR27","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1007\/BF03345745","volume":"32","author":"S Shahani","year":"2009","unstructured":"S. Shahani, M. Braga-Basaria, M. Maggio, S. Basaria, Androgens and erythropoiesis: past and present. J. Endocrinol. Investig. 32(8), 704\u2013716 (2009). https:\/\/doi.org\/10.1007\/BF03345745","journal-title":"J. Endocrinol. Investig."},{"issue":"5","key":"4150_CR28","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1016\/j.fertnstert.2011.01.038","volume":"95","author":"HF Escobar-Morreale","year":"2011","unstructured":"H.F. Escobar-Morreale, M. Luque-Ram\u00edrez, Role of androgen-mediated enhancement of erythropoiesis in the increased body iron stores of patients with polycystic ovary syndrome. Fertil. Steril. 95(5), 1730\u20135.e1 (2011). https:\/\/doi.org\/10.1016\/j.fertnstert.2011.01.038","journal-title":"Fertil. Steril."},{"issue":"7","key":"4150_CR29","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1038\/s41366-023-01299-0","volume":"47","author":"C Hilton","year":"2023","unstructured":"C. Hilton, R. Sabaratnam, H. Drakesmith, F. Karpe, Iron, glucose and fat metabolism and obesity: an intertwined relationship. Int. J. Obes. 47(7), 554\u2013563 (2023). https:\/\/doi.org\/10.1038\/s41366-023-01299-0","journal-title":"Int. J. Obes."},{"issue":"Suppl 2","key":"4150_CR30","doi-asserted-by":"publisher","first-page":"S983","DOI":"10.1016\/j.dsx.2017.07.026","volume":"11","author":"LG Aguirre","year":"2017","unstructured":"L.G. Aguirre, D. Urrunaga-Pastor, E. Moncada-Mapelli et al., High serum ferritin levels are associated with insulin resistance but not with impaired glucose tolerance in a healthy people population. Diab. Metab. Syndr. 11(Suppl 2), S983\u2013S988 (2017). https:\/\/doi.org\/10.1016\/j.dsx.2017.07.026","journal-title":"Diab. Metab. Syndr."},{"issue":"2","key":"4150_CR31","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1530\/eje.1.02083","volume":"154","author":"CE Wrede","year":"2006","unstructured":"C.E. Wrede, R. Buettner, L.C. Bollheimer, J. Sch\u00f6lmerich, K.D. Palitzsch, C. Hellerbrand, Association between serum ferritin and the insulin resistance syndrome in a representative population. Eur. J. Endocrinol. 154(2), 333\u2013340 (2006). https:\/\/doi.org\/10.1530\/eje.1.02083","journal-title":"Eur. J. Endocrinol."},{"issue":"7","key":"4150_CR32","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.bbagen.2008.04.005","volume":"1790","author":"SN Rajpathak","year":"2009","unstructured":"S.N. Rajpathak, J.P. Crandall, J. Wylie-Rosett, G.C. Kabat, T.E. Rohan, F.B. Hu, The role of iron in type 2 diabetes in humans. Biochim. Biophys. Acta 1790(7), 671\u2013681 (2009). https:\/\/doi.org\/10.1016\/j.bbagen.2008.04.005","journal-title":"Biochim. Biophys. Acta"},{"issue":"3","key":"4150_CR33","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1210\/jc.2010-2211","volume":"96","author":"M Luque-Ram\u00edrez","year":"2011","unstructured":"M. Luque-Ram\u00edrez, F. \u00c1lvarez-Blasco, M. Alpa\u00f1\u00e9s, H.F. Escobar-Morreale, Role of decreased circulating hepcidin concentrations in the iron excess of women with the polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 96(3), 846\u2013852 (2011). https:\/\/doi.org\/10.1210\/jc.2010-2211","journal-title":"J. Clin. Endocrinol. Metab."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-024-04150-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-024-04150-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-024-04150-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T14:22:19Z","timestamp":1740147739000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-024-04150-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,30]]},"references-count":33,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["4150"],"URL":"https:\/\/doi.org\/10.1007\/s12020-024-04150-2","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,30]]},"assertion":[{"value":"3 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was conducted in agreement with the Declaration of Helsinki II and was approved by Kartal Dr. Lutfi Kirdar City Hospital Ethical Committee (reference number: 2024\/0l0.99\/2\/49, date: 27.03.2024).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}